Drug__r.Drug_Code__c,Diagnosis__c,Hierarchy__c
100extrabgts,Gestational diabetes,Primary
100extrabgts,"Occupations where hypoglycemia presents a significant safety risk (e.g., pilots, air traffic controllers, commercial drivers)",Primary
100extrabgts,"Changes in drug therapy that may impact blood glucose control (e.g., starting or stopping hypo- or hyperglycemic inducing medications, or drug-to-drug or drug-to-disease interactions)",Primary
100extrabgts,Acute illness or comorbidities that may impact blood glucose control,Primary
100extrabgts,"Not meeting glycemic targets, as determined by a physician, for 3 months or more",Primary
100extrabgts,Other,
1PPIpant,Barrett's esophagus,Primary
1PPIpant,Zollinger-Ellison syndrome,Primary
1PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
1PPIpant,Other,
1PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
1PPIpant,Gastric ulcer,Primary
1PPIpant,Reflux esophagitis,Primary
1PPIpant,Gastroesophageal reflux disease (GERD),Primary
1PPIpant,Duodenal ulcer,Primary
1PPIrabe,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
1PPIrabe,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
1PPIrabe,Barrett's esophagus,Primary
1PPIrabe,Gastric ulcer,Primary
1PPIrabe,Duodenal ulcer,Primary
1PPIrabe,Other,
1PPIrabe,Gastroesophageal reflux disease (GERD),Primary
1PPIrabe,Reflux esophagitis,Primary
1PPIrabe,Zollinger-Ellison syndrome,Primary
2PPIesom,Barrett's esophagus,Primary
2PPIesom,Zollinger-Ellison syndrome,Primary
2PPIesom,Duodenal ulcer,Primary
2PPIesom,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
2PPIesom,Gastric ulcer,Primary
2PPIesom,Gastroesophageal reflux disease (GERD),Primary
2PPIesom,Reflux esophagitis,Primary
2PPIesom,Other,
2PPIesom,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
2PPIlans,Other,
2PPIlans,Gastroesophageal reflux disease (GERD),Primary
2PPIlans,Reflux esophagitis,Primary
2PPIlans,Duodenal ulcer,Primary
2PPIlans,Gastric ulcer,Primary
2PPIlans,Barrett's esophagus,Primary
2PPIlans,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
2PPIlans,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
2PPIlans,Zollinger-Ellison syndrome,Primary
2PPIomep,Zollinger-Ellison syndrome,Primary
2PPIomep,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
2PPIomep,Reflux esophagitis,Primary
2PPIomep,Gastroesophageal reflux disease (GERD),Primary
2PPIomep,Duodenal ulcer,Primary
2PPIomep,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
2PPIomep,Barrett's esophagus,Primary
2PPIomep,Gastric ulcer,Primary
2PPIomep,Other,
2PPIpant,Reflux esophagitis,Primary
2PPIpant,Duodenal ulcer,Primary
2PPIpant,Gastric ulcer,Primary
2PPIpant,Patient has contraindications to one or more 1st line PPIs,Primary
2PPIpant,Zollinger-Ellison syndrome,Primary
2PPIpant,Barrett's esophagus,Primary
2PPIpant,"Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)",Primary
2PPIpant,Other,
2PPIpant,Previously tried Proton Pump Inhibitors - rabeprazole AND pantoprazole magnesium,Primary
2PPIpant,Gastroesophageal reflux disease (GERD),Primary
2PPIpant,"Connective tissue disease (e.g., lupus, scleroderma, crest),",Primary
abatacept,Rheumatoid Arthritis,Primary
abatacept,Polyarticular Juvenile Idiopathic Arthritis (pJIA),Primary
abatacept,Other,
abobotulinum,cervical dystonia (spasmodic torticollis) in adults.,Primary
abobotulinum,focal spasticity,Primary
abobotulinum,Other,
ACEIcapt,Other,
ACEIcapt,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIcapt,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIcila,Other,
ACEIcila,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIcila,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIdena,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIdena,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIdena,Other,
ACEIenap,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIenap,other,
ACEIenap,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIfosi,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIfosi,Other,
ACEIfosi,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIliso,Other,
ACEIliso,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIliso,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIperi,Other,
ACEIperi,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIperi,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEIquin,Complex patient requiring medication(s) for co-existing chronic condition(s),Primary
ACEIquin,Other,
ACEIquin,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
ACEItran,Requiring medication(s) for co-existing chronic condition(s),Primary
ACEItran,Other,
ACEItran,"Treatment failure on optimal doses of, or intolerance to, ramipril",Primary
acetaminophen,Treatment of osteoarthritis only as monotherapy.,Primary
acetaminophen,Treatment osteoarthritis as an adjunct to NSAID therapy when additional pain relief is required.,Primary
acetaminophen,Other,
adalimumab,Plaque Psoriasis,Primary
adalimumab,Hidradentis Suppurativa,Primary
adalimumab,Rheumatoid Arthritis,Primary
adalimumab,Moderate to Severe Active Crohn's,Primary
adalimumab,Other,
adalimumab,Psoriatic Arthritis,Primary
adalimumab,Ulcerative Colitis,Primary
adalimumab,Ankylosing Spondylitis,Primary
adalimumab,Polyarticular Juvenile Idiopathic Arthritis,Primary
adalimumab,Fistulizing Crohn's,Primary
ADHDamph,Other,
ADHDamph,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning.",Primary
ADHDatom,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning.",Primary
ADHDatom,Other,
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR",Primary
ADHDlisd,Other,
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR",Primary
ADHDlisd,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - other",Primary
ADHDmeth,Other,
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - other",Primary
ADHDmeth,"Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity, impulsivity, or inattention that interferes with functioning and - dextroamphetamine IR/SR",Primary
ADHDmeth,"ADHD with hyperactivity, impulsivity, or inattention that interferes with functioning and - methylphenidate IR/SR",Primary
ADTIdone,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
ADTIdone,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
ADTIdone,Other,
ADTIgala,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
ADTIgala,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
ADTIgala,Other,
ADTIriva,"Initial - mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
ADTIriva,Other,
ADTIriva,"Renewal -  mild to moderate Alzheimer’s disease, Alzheimer’s disease with a vascular component, Alzheimer’s disease with Parkinsonian features (Lewy bodies), or mixed dementia with Alzheimer’s disease",Primary
afibdaba,Patient has a diagnosis of non-valvular atrial fibrillation,Primary
afibdaba,Other,
aggrenox,Other,
aggrenox,For secondary prevention of cerebrovascular occlusion and embolization in patients who have experienced recurrent TIA OR stroke while receiving ASA alone,Primary
alemtuzumab,As monotherapy for the treatment of relapsing-remitting multiple sclerosis,Primary
alenalen,clinical or radiographically documented fracture due to osteoporosis,Primary
alenalen,Other,
alenalen,Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg of prednisone per day or greater AND for 90 consecutive days or longer.,Primary
alenrise,Clinical or radiographically documented fracture due to osteoporosis,Primary
alenrise,Glucocorticoid-induced osteoporosis,Primary
alenrise,Other,
alitretinoin,Other,
alitretinoin,For the treatment of severe chronic hand eczema ,Primary
antiemeticgran,Prescribed for the prevention and treatment of nausea and vomiting associated with chemotherapy,Primary
antiemeticgran,Other,
antiemeticonda,Other,
antiemeticonda,Prevention and treatment of nausea and vomiting associated with chemotherapy,Primary
antifungalciclo,Other,
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - diabetes,Primary
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - circulatory condition,Primary
antifungalciclo,Diagnosis of a fungal infection of the lower extremities - other,Primary
antifungalclio,Diagnosis of a fungal infection of the lower extremities - diabetes,Primary
antifungalclio,Other,
antifungalclio,Diagnosis of a fungal infection of the lower extremities - other,Primary
antifungalclio,Diagnosis of a fungal infection of the lower extremities - circulatory condition,Primary
antifungalclot,Diagnosis of a fungal infection of the lower extremities - other,Primary
antifungalclot,Diagnosis of a fungal infection of the lower extremities - circulatory condition,Primary
antifungalclot,Diagnosis of a fungal infection of the lower extremities - diabetes,Primary
antifungalclot,Other,
antifungalketo,Other,
antifungalketo,Diagnosis of a fungal infection of the lower extremities - circulatory condition,Primary
antifungalketo,Diagnosis of a fungal infection of the lower extremities - diabetes,Primary
antifungalketo,Diagnosis of a fungal infection of the lower extremities - other,Primary
antifungalmico,Other,
antifungalmico,Diagnosis of a fungal infection of the lower extremities - diabetes,Primary
antifungalmico,Diagnosis of a fungal infection of the lower extremities - circulatory condition,Primary
antifungalmico,Diagnosis of a fungal infection of the lower extremities - other,Primary
apomorphine,"For the acute, intermittent treatment of patients with advanced Parkinson's disease",Primary
apomorphine,Other,
aprepitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy (HEC).,Primary
aprepitant,Other,
ARBcand,Patient has experienced intractable cough,Primary
ARBcand,Patient has experienced angioedema,Primary
ARBcand,Other,
ARBepro,Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried,Primary
ARBepro,Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I): ALL reference ARBs must have been unsucessfully tried,Primary
ARBepro,Other,
ARBirbe,Patient has experienced intractable cough,Primary
ARBirbe,Other,
ARBirbe,Patient has experienced angioedema,Primary
ARBlosa,Patient has experienced angioedema,Primary
ARBlosa,Patient has experienced intractable cough,Primary
ARBlosa,Other,
ARBolme,Other,
ARBolme,Patient has experienced intractable cough,Primary
ARBolme,Patient has experienced angioedema,Primary
ARBtelm,Patient has experienced angioedema,Primary
ARBtelm,Patient has experienced intractable cough,Primary
ARBtelm,Other,
ARBvals,Other,
ARBvals,Patient has experienced angioedema,Primary
ARBvals,Patient has experienced intractable cough,Primary
aripip,Schizophrenia,Primary
aripip,Other,
aripip,Other psychosis (not dementia related),Primary
asenapine,Diagnosis of Bipolar I Disorder,Primary
asenapine,Other,
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
Avonex,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
azet,Other,
azet,A deteriorating clinical condition despite treatment with inhaled tobramycin,Primary
azet,For the cyclic treatment of chronic Pseudomonas aeruginosa infections in patients with moderate to severe cystic fibrosis,Primary
baclofen,Severe spasticity due to multiple sclerosis,Primary
baclofen,Severe spasticity due to spinal cord injury,Primary
baclofen,Other,
benralizumab,severe eosinophilic asthma,Primary
benralizumab,other,
benzydamine,"For the treatment of mucositis, ulcerative complications of chemotherapy",Primary
benzydamine,Immunocompromised patients at risk of mucosal breakdown.,Primary
BPHDUTA,other,
BPHDUTA,Diagnosis of benign prostatic hyperplasia (BPH),Primary
BPHFINA,Diagnosis of benign prostatic hyperplasia (BPH),Primary
BPHFINA,other,
brex,Other psychosis (not dementia related),Primary
brex,Schizophrenia,Primary
brex,Other,
budcaps,Crohn's disease,Primary
budcaps,Other,
budenema,Ulcerative Colitis,Primary
budenema,Other,
bupre inj,Patient is an adult and have been induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days,Primary
bupre inj,Exceptional coverage consideration,Primary
bupropiondepression,Other,
bupropiondepression,Depression,Primary
cad,diagnosis of CAD and PAD,Primary
cad,Other,
carv,For treatment of stable symptomatic congestive heart failure:,Primary
carv,Concurrent therapy with an Angiotensin Converting Enzyme inhibitor (ACE-I),Primary
carv,Unable to take ACE-I (provide details):,Primary
CCBfelo,Complex patient requiring medications for co-existing chronic condition(s),Primary
CCBfelo,"Treatment failure on optimal dose of, or intolerance to, amlodipine",Primary
CCBfelo,Other,
CCBnife,Other,
CCBnife,Complex patient requiring medications for co-existing chronic condition(s),Primary
CCBnife,"Treatment failure on optimal dose of, or intolerance to, amlodipine",Primary
celecox,Other,
celecox,Lupus,Primary
celecox,Ankylosing Spondylitis,Primary
celecox,Rheumatoid Arthritis,Primary
celecox,Psoriatic Arthritis,Primary
celecox,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen.",Primary
celecox,Gout,Primary
certo,Rheumatoid Arthritis,Primary
certo,Other,
certo,Psoriatic Arthritis,Primary
certo,Ankylosing Spondylitis,Primary
chlorambucil,Other,
chlorambucil,Lupus,Primary
chlorambucil,Vasculitis,Primary
chloroquine,Lupus,Primary
chloroquine,Rheumatoid Arthritis,Primary
chloroquine,Treatment of extraintestinal amebiasis,Primary
chloroquine,Other,
ciproophthcipr,Other,
ciproophthcipr,Failure or intolerance to first-line agents (e.g. aminoglycosides),Primary
clobazam,Treatment of anxiety,Primary
clobazam,Other,
codeine,For pain management in a specified chronic pain diagnosis,Primary
codeine,Other,
codeine,Diagnosis of cancer,Primary
COPDaclid,Diagnosis of chronic obstructive pulmonary disease (COPD),Primary
COPDaclid,Other,
COPDaclidform,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted. ,Primary
COPDaclidform,Other,
COPDflutsalm,Other,
COPDflutsalm,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted,Primary
COPDflutumecvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted,Primary
COPDflutumecvila,Other,
COPDflutvila,Other,
COPDflutvila,Diagnosis of moderate to very severe COPD with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted,Primary
COPDglyc,Other,
COPDglyc,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium,Primary
COPDinda,Other,
COPDinda,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs),Primary
COPDindaglyc,Other,
COPDindaglyc,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA,Primary
COPDsalm,Diagnosis of COPD with a post-bronchodilator FEV1/FVC < 0.70 AND contraindication or intolerance to a long-acting muscarinic receptor antagonist (LAMAs),Primary
COPDsalm,Other,
COPDtiop,Other,
COPDtiop,Diagnosis of chronic obstructive pulmonary disease (COPD) AND failureof both tiotropium and umeclidinium,Primary
COPDtiopolod,Other,
COPDtiopolod,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA,Primary
COPDumecvila,Diagnosis of moderate to very severe COPD¹ with a post-bronchodilator FEV1/FVC < 0.70 AND FEV1 < 80% predicted AND inadequate response after minimum of 6 month trial of either LAMA or LABA,Primary
COPDumecvila,Other,
cyclosporin,Nephrotic syndrome,Primary
cyclosporin,Treatment failure on topical corticosteroid,Primary
cyclosporin,Psoriasis of the palms and/or soles severe enough to interfere with daily living or work,Primary
cyclosporin,Extensive psoriasis involving at least 25% of body surface or having psoriasis area and severity index of at least 12,Primary
cyclosporin,Other,
cyclosporin,UVB/UVA light therapy is not available,Primary
cyclosporin,Rheumatoid Arthritis,Primary
cyclosporin,Severe ocular inflammatory disease,Primary
cyclosporin,Ultraviolet-B light or oral or topical methoxsalen plus ultraviolet-A ligh,Primary
cyclosporin,Topical therapy with corticosteroids,Primary
cyproinj,Indication of need to reduce aggressive sexual drive,Primary
cyproinj,Other,
cyprooral,Other,
cyprooral,Indication of need to reduce aggressive sexual drive,Primary
dalteparin,Other,
dalteparin,Prophylaxis of venous thromboembolism,Primary
dalteparin,Treatment of venous thromboembolism associated with cancer,Primary
dalteparin,Treatment of venous thromboembolism,Primary
deferprox,Acquired disease,Primary
deferprox,Other,
deferprox,Congenital disease,Primary
defersirox,Congenital disease,Primary
defersirox,Acquired disease,Primary
defersirox,Other,
denosacla,Other,
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates,Primary
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia,Primary
denosacla,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other,Primary
denosprol,Other,
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - immune-mediated hypersensitivity reaction to oral bisphosphonates,Primary
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia,Primary
denosprol,osteoporosis WITH fracture due to osteoporosis AND a contraindication to oral bisphosphonates - other,Primary
desmopressin,Other,
desmopressin,Treatment of diabetes insipidus,Primary
diclo,Gout,Primary
diclo,Psoriatic Arthritis,Primary
diclo,Lupus,Primary
diclo,Ankylosing Spondylitis,Primary
diclo,Rheumatoid Arthritis,Primary
diclo,Other,
diclomiso,Rheumatoid Arthritis,Primary
diclomiso,Psoriatic Arthritis,Primary
diclomiso,Ankylosing Spondylitis,Primary
diclomiso,Lupus,Primary
diclomiso,Gout,Primary
diclomiso,Other,
dienogest,For the management of pelvic pain associated with endometriosis,Primary
dienogest,Unable to use combined hormonal contraceptives,Primary
dienogest,Other,
dienogest,Experienced treatment failure on combined hormonal contraceptives,Primary
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
dimethylfumarate,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
DOACapix,Other,
DOACapix,Deep Vein Thrombosis (DVT),Primary
DOACapix,Non-valvular Atrial Fibrillation,Primary
DOACapix,Pulmonary Embolism (PE),Primary
DOACriva,Pulmonary embolism (PE),Primary
DOACriva,Deep vein thrombosis (DVT),Primary
DOACriva,Other,
DOACriva,Non-valvular atrial fibrillation,Primary
dorzolamide,Other,
dorzolamide,Diagnosis of ocular hypertension and open-angle glaucoma in patients with a demonstrated allergy to preservative,Primary
DPP4lina,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea,Primary
DPP4lina,Type 2 diabetes - Dual therapy of metformin and an insulin,Primary
DPP4lina,Other,
DPP4lina,Type 2 diabetes - trial of one agent,Primary
DPP4saxa,Other,
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea,Primary
DPP4saxa,Type 2 diabetes - trial of one agent,Primary
DPP4saxa,Type 2 diabetes - Dual therapy of metformin and an insulin,Primary
dronedarone,Other,
dronedarone,"For long-term rhythm control of atrial fibrillation (AF) who successfully achieved rhythm control on amiodarone, but who have developed intolerable adverse effects to amiodarone (NOT including liver adverse effects)",Primary
duloxetine,For the treatment of neuropathic pain,Primary
duloxetine,Other,
duodopa,Patient experiences severe disability despite having tried frequent dosing of levodopa,Primary
duodopa,For the management of severe cases of advanced idiopathic Parkinson's Disease,Primary
edaravone,Initial Request - Diagnosis of probable amyotrophic lateral sclerosis (ALS) or definite ALS,Primary
edaravone,Renewal Request,Primary
edaravone,Other,
enoxaparin,Prophylaxis of venous thromboembolism,Primary
enoxaparin,Other,
enoxaparin,Treatment of venous thromboembolism,Primary
entacapone,Parkinson's Disease - As adjunct therapy for patients with an inadequate response after alterations of levodopa/carbidopa doses.,Primary
entacapone,Other,
entacapone,Other,
entecavir,Other,
entecavir,Chronic Hepatitis B,Primary
Entresto,Other,
Entresto,Patient has heart failure with New York Heart Association (NYHA) Class II to III symptoms - despite at least four weeks of treatment at the optimum stable dose of a beta-blocker and other recommended therapies,Primary
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Genotype 1 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Genotype 2 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genptype 3 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Genotype 4 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Genotype 5 - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,Genotype 6 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,Mixed genotype - Treatment-naive or treatment-experienced¹ with decompensated cirrhosis: velpatasvir plus sofosbuvir with ribavirin for 12 weeks.,Primary
epclusa,liver transplant recipient,Primary
epclusa,Genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: velpatasvir plus sofosbuvir for 12 weeks.,Primary
epclusa,lung transplant recipient,Primary
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and inadequate response to non-prostanoid therapies",Primary
epoprostenol,"As monotherapy, for the treatment of WHO/NYHA functional class IV PAH and contraindication to the non-prostanoid therapies",Primary
epoprostenol,Other,
eslicarbazepine,Other,
eslicarbazepine,Adjunctive therapy for partial-onset seizures in adults after other medications have been tried without success,Primary
estraderm,For indications of menopausal and post-menopausal symptoms - Extreme intolerance to oral preparations,Primary
estraderm,For indications of menopausal and post-menopausal symptoms - Diagnosis of severe liver disease,Primary
estraderm,For indications of menopausal and post-menopausal symptoms - other,Primary
estraderm,Other,
etanbiosim,Psoriatic Arthritis,Primary
etanbiosim,Plaque Psoriasis,Primary
etanbiosim,Ankylosing Spondylitis,Primary
etanbiosim,Other,
etanbiosim,Rheumatoid Arthritis,Primary
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Simon Broome criteria",Primary
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Dutch Lipid Network criteria",Primary
evo,Renewal Request - LDL-C is reduced by at least 40% from the LDL prior to treatment with evolocumab,Primary
evo,"Initial Request - Diagnosis of ""definite"" or ""probable"" Heterozygous Familial Hypercholesterolemia (HeFH) - Genetic testing",Primary
ezetimibe,Other,
ezetimibe,Patient has a diagnosis of hypercholesterolemia.,Primary
febuxostat,For the reduction of serum uric acid levels in patients with gout who demonstrate an immune-mediated hypersensitivity reaction to allopurinol,Primary
febuxostat,Other,
fent patch,Diagnosis of cancer,Primary
fent patch,For pain management in a specified chronic pain diagnosis,Primary
fent patch,Other,
fidaxomicin,treatment of C. Difficile - documented allergy,Primary
fidaxomicin,treatment of C. Difficile - severe intolerance to oral vancomycin,Primary
fidaxomicin,treatment of C. Difficile - failure of oral vancomycin AND when retreatment with vancomycin is not an option AND when the patient is at high risk of hospitalization,Primary
fidaxomicin,Other,
filgrastim,Post-BMT to stimulate bone marrow engraftment,Primary
filgrastim,Post-BMT for rescue of failure to engraft,Primary
filgrastim,For rescue of prolonged febrile neutropenia following chemotherapy,Primary
filgrastim,Cancer patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy,Primary
filgrastim,For PRIMARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy regimens,Primary
filgrastim,For SECONDARY prophylaxis of febrile neutropenia in cancer patients receiving potentially CURATIVE myelosuppressive chemotherapy,Primary
filgrastim,Myelodysplastic disorders or aplastic anemia awaiting bone marrow transplantation,Primary
filgrastim,Chronic benign cyclical neutropenia,Primary
fingolimod,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis,Primary
fingolimod,other,
fluconsolids,Immunocompromised patient,Primary
fluconsolids,Exceptions on an individual basis for fungal infections resistant to first-line medications.,Primary
fluconsolids,Other,
gabapentin,Diagnosis of Bipolar Disorder,Primary
gabapentin,Other,
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
glatiramer,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
gliclazide,"Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses.",Primary
gliclazide,Other,
golim,Ankylosing Spondylitis,Primary
golim,Psoriatic Arthritis,Primary
golim,Other,
golim,Rheumatoid Arthritis,Primary
goserelin,Patient has a diagnosis of endometriosis,Primary
goserelin,Other,
H2Bcime,"Treatment failure on prescription dose of, or intolerance to, ranitidine",Primary
H2Bcime,Other,
H2Bfamo,Other,
H2Bfamo,"Treatment failure on prescription dose of, or intolerance to, ranitidine",Primary
H2Bniza,Other,
H2Bniza,"Treatment failure on prescription dose of, or intolerance to, ranitidine",Primary
harvoni,Genotype 1 - Treatment-experienced² with compensated cirrhosis¹: 24 weeks.,Primary
harvoni,"Genotype 1 - Liver transplant recipients, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹:  (with RBV) for 12 weeks.",Primary
harvoni,"Genotype 1 - Treatment-naive, mono-HCV infected, fibrosis stage < F3 and HCV RNA < 6 million IU/mL (only considered for non-cirrhotic patients): 8 weeks.",Primary
harvoni,Genotype 1 - Treatment-naive with no cirrhosis (including advanced fibrosis stage ≥ 3) or with compensated cirrhosis¹: 12 weeks.,Primary
harvoni,Genotype 1 - Treatment-naive or treatment-experienced² with decompensated cirrhosis³: (with RBV) for 12 weeks.,Primary
harvoni,Genotype 1 - Treatment-experienced² with no cirrhosis:  12 weeks.,Primary
harvoni,"Genotype 1 - HIV/HCV-1 co-infected, treatment-naive or treatment-experienced² with no cirrhosis or with compensated cirrhosis¹: 12 weeks.",Primary
Humira,Ankylosing Spondylitis,Primary
Humira,Rheumatoid Arthritis,Primary
Humira,Other,
Humira,Psoriatic Arthritis,Primary
Humira,Ulcerative Colitis,Primary
Humira,Polyarticular Juvenile Idiopathic Arthritis,Primary
Humira,Moderate to Severe Active Crohn's,Primary
Humira,Fistulizing Crohn's,Primary
Humira,Plaque Psoriasis,Primary
Humira,Hidradenitis Suppurativa,Primary
hydromorph50inj,"Relief of severe pain in patients who require subcutaneously, intravenously or intramuscularly administered opioids in doses or concentrations higher than those usually needed",Primary
hydromorph50inj,Other,
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND regular release dosage forms of hydromorphone,Primary
hydromorphSR,Pain management in a specified chronic pain (including cancer pain) diagnosis AND sustained release preparations of morphine,Primary
hydromorphSR,Other,
hydroxyurea,Patient has a diagnosis of pustular psoriasis ,Primary
hydroxyurea,Other,
hydroxyzine,For the treatment of anxiety,Primary
hydroxyzine,Other,
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type I,Primary
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - type II,Primary
icat,Initial Request - For the treatment of acute attacks of hereditary angioedema (HAE) - other,Primary
icat,Renewal Request - Patient is limited to a single dose for self-administration per attack,Primary
incobot,For the treatment of blepharospasm,Primary
incobot,For the treatment of cervical dystonia of a predominantly rotational form (Spasmodic Torticollis),Primary
incobot,For the treatment of post-stroke spasticity of the upper limb,Primary
incobot,Other,
indapamide,Treatment failure or intolerance to a thiazide diuretic,Primary
indapamide,Other,
inflix,Moderate to Severe Active Crohn's,Primary
inflix,Fistulizing Crohns,Primary
inflix,Other,
inflix,Ulcerative Colitis,Primary
inflix,Rheumatoid Arthritis,Primary
inflix,Ankylosing Spondylitis,Primary
inflix,Psoriatic Arthritis,Primary
inflix,Plaque Psoriasis,Primary
interferonA,"Chronic Hepatitis B, non-cirrhosis",Primary
interferonA,Other,
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - switch,Primary
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - renewal,Primary
interferonB1B,As monotherapy for secondary progressive multiple sclerosis (SPMS) - initial,Primary
interferonB1B,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
isavuconazole,For the treatment of Invasive Mucormycosis (IM) in adults when prescribed by infectious disease specialist and if a patient is established on isavuconazole in hospital,Primary
isavuconazole,Other,
ismn,Diagnosis of unstable angina,Primary
ismn,Experienced treatment failure on optimal dose of isosorbide dinitrate (ISDN),Primary
ismn,Other,
ismn,Experienced intolerance to isosorbide dinitrate (ISDN),Primary
itraconazole,Immunocompromised patient,Primary
itraconazole,Other,
itraconazole,Pulse treatment for severe onychomycosis with functional disability,Primary
ivabradine,Patient has stable heart failure with New York Heart Association Class II or III symptoms,Primary
ivabradine,"NYHA class II or III symptoms that have persisted despite at least four weeks of treatment at the optimum stable dose of a B-blocker, an aldosterone antagonist AND an ACEI or an ARB",Primary
ivabradine,Other,
ixekiz,Other,
ixekiz,Plaque Psoriasis,Primary
LABAflutsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.,Primary
LABAflutsalm,Other,
LABAflutvila,Other,
LABAflutvila,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.,Primary
LABAform,Other,
LABAform,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.,Primary
LABAformbude,Other,
LABAformbude,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.,Primary
LABAformmom,Other,
LABAformmom,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid.,Primary
LABAsalm,Other,
LABAsalm,Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid,Primary
lacolaco,Other,
lacolaco,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures,Primary
lacopera,At least four other anti-epileptic medications have been tried without success,Primary
lacopera,For adjunctive therapy (to be used in combination with at least ONE other anti-epileptic drug) for partial-onset seizures,Primary
lacopera,Other,
lactulose,Treatment of portal systemic encephalopathy,Primary
lactulose,Treatment of liver failure,Primary
lactulose,Other,
LAinsulinbasa,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment",Primary
LAinsulinbasa,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management,Primary
LAinsulinbasa,Patient has a contraindication to NPH insulin,Primary
LAinsulinbasa,Other,
Lainsulindete,Patient has a contraindication to NPH insulin,Primary
Lainsulindete,"Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced or continues to experience severe, systemic or local allergic reaction to existing insulin treatment",Primary
Lainsulindete,Patient is currently taking NPH insulin (and/or pre-mix insulin) and has experienced unexplained nocturnal hypoglycemia at least once a month despite optimal management,Primary
Lainsulindete,Other,
lamivudine,Chronic Hepatitis B,Primary
lamivudine,Other,
lamivudine,Other - Hepatitis B reactivation prophylaxis while on immunosuppressants,Primary
LBMdiph,For the treatment of diarrhea due to a specified chronic illness,Primary
LBMdiph,Other,
LBMlope,For the treatment of diarrhea due to a specified chronic illness,Primary
LBMlope,Other,
leflunomide,Rheumatoid Arthritis,Primary
leflunomide,Other,
leuprolide,Diagnosis of precocious puberty,Primary
leuprolide,Other,
leuprolide,Diagnosis indicating need to reduce sexual drive,Primary
leuprolide,Diagnosis of endometriosis,Primary
levetiracetam,Diagnosis of epilepsy,Primary
levetiracetam,Other,
linezolid,Treatment of vancomycin resistant enterococcus (VRE) infections,Primary
linezolid,Other,
linezolid,Treatment of methicillin-resistant staphylococcus aureus (MRSA) in patients who are unresponsvie to or intolerant of injectable vancomycin,Primary
Maintenaarip,For management of manifestations of related psychotic disorders (not dementia-related),Primary
Maintenaarip,For management of manifestations of schizophrenia,Primary
Maintenaarip,Other,
Maintenapalisust,Other,
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia,Primary
Maintenapalisust,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations,Primary
Maintenapalisust,For management of manifestations of schizophrenia,Primary
Maintenapalisust,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled",Primary
Maintenapalitrin,For management of manifestations of schizophrenia,Primary
Maintenapalitrin,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled",Primary
Maintenapalitrin,Other,
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations,Primary
Maintenapalitrin,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia,Primary
Maintenarisp,Other,
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations,Primary
Maintenarisp,"For management of manifestations of related psychotic disorders (not dementia-related) - have tried oral aripiprazole, risperidone, or paliperidone PLUS at least one other antipsychotic agent AND continues to be inadequately controlled",Primary
Maintenarisp,For management of manifestations of related psychotic disorders (not dementia-related) - are currently receiving a conventional depot antispychotic PLUS experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia,Primary
Maintenarisp,For management of manifestations of schizophrenia,Primary
maviret,"Genotype 1 - Previously treated⁴ with an NS5A inhibitor-containing regimen, but NS3/4A protease inhibitor treatment-naive: 16 weeks",Primary
maviret,"Genotype 1 - Previously treated³ with an NS3/4A protease inhibitor-containing regimen, but NS5A inhibitor treatment-naive: 12 weeks.",Primary
maviret,Genotype 1 - Treatment-experienced¹ with compensated cirrhosis²: 12 weeks,Primary
maviret,Genotype 1 - Treatment-experienced¹ with no cirrhosis: for 8 weeks,Primary
maviret,Genotype 1 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
maviret,Genotype 6 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.,Primary
maviret,kidnet transplant recipient,Primary
maviret,heart transplant recipient,Primary
maviret,Genotype 5 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.,Primary
maviret,genotype 6 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
maviret,genotype 4 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
maviret,Genotype 4 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.,Primary
maviret,Genotype 4 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.,Primary
maviret,genotype 5 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
maviret,Genotype 5 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.,Primary
maviret,Genotype 6 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.,Primary
maviret,genotype 2 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
maviret,Genotype 2 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.,Primary
maviret,Genotype 2 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.,Primary
maviret,Genotype 3 - Treatment-experienced¹ with compensated cirrhosis²: for 12 weeks.,Primary
maviret,Genotype 3 - Treatment-experienced¹ with no cirrhosis: for 8 weeks.,Primary
maviret,genotype 3 - Treatment-naive with no cirrhosis or with compensated cirrhosis²: for 8 weeks,Primary
meloxicam,Lupus,Primary
meloxicam,Ankylosing Spondylitis,Primary
meloxicam,Psoriatic Arthritis,Primary
meloxicam,Rheumatoid Arthritis,Primary
meloxicam,Other,
meloxicam,"Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen",Primary
meloxicam,Gout,Primary
mepolizumab,other,
mepolizumab,severe eosinophilic asthma,Primary
mercaptopurine,Crohn's disease,Primary
mercaptopurine,Other,
mercaptopurine,Ulcerative Colitis,Primary
mercaptopurine,Autoimmune hepatitis,Primary
mercaptopurine,Inflammatory bowel disease,Primary
methotrexatePFsyringe,Other,
methotrexatePFsyringe,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate",Primary
methotrexateVial,"Treatment of rheumatoid arthritis, when the patient demonstrates failure on or intolerance to oral methotrexate",Primary
methotrexateVial,Other,
miniMed,Other form of diabetes (please specify):,Primary
miniMed,Type 1 diabetes,Primary
mmf,Autoimmune hepatitis,Primary
mmf,Bullous pemphigold,Primary
mmf,Other,
modafinil,Other,
modafinil,Treatment of narcolepsy,Primary
mometNS,Other,
mometNS,Diagnosis of allergic rhinitis in child 3-11 years old,Primary
nabumetone,Lupus,Primary
nabumetone,Psoriatic Arthritis,Primary
nabumetone,Ankylosing Spondylitis,Primary
nabumetone,Gout,Primary
nabumetone,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
nabumetone,Rheumatoid Arthritis,Primary
nabumetone,Other,
nadroparin,Treatment of venous thromboembolism,Primary
nadroparin,Prophylaxis of venous thromboembolism,Primary
nadroparin,Other,
naproEC,Psoriatic Arthritis,Primary
naproEC,Ankylosing Spondylitis,Primary
naproEC,Rheumatoid Arthritis,Primary
naproEC,Other,
naproEC,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen",Primary
naproEC,Lupus,Primary
naproEC,Gout,Primary
natalizumab,As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis,Primary
natalizumab,other,
nebulesbude,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.,Primary
nebulesbude,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily,Primary
nebulesbude,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece,Primary
nebulesbude,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination,Primary
nebulesbude,Other,
nebulescrom,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices,Primary
nebulescrom,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece,Primary
nebulescrom,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily,Primary
nebulescrom,Other,
nebulescrom,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.,Primary
nebulesipra,Other,
nebulesipra,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily,Primary
nebulesipra,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber,Primary
nebulesipra,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices,Primary
nebulesipra,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece,Primary
nebulesiprasalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices,Primary
nebulesiprasalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily,Primary
nebulesiprasalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber,Primary
nebulesiprasalb,Other,
nebulesiprasalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece,Primary
nebulessalb,Other,
nebulessalb,Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece,Primary
nebulessalb,Person who has difficulty in generating adequate inspiratory effort that he/she is unable to achieve therapeutic benefit from an inhaler with an aerochamber.,Primary
nebulessalb,Resident of a long-term facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily,Primary
nebulessalb,Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor coordination to a degree that precludes effective inhaler techniques even when aided by inhaler-assistance devices,Primary
netupitant,For the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy in combination with dexamethasone,Primary
netupitant,Other,
nintedanib,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF),Primary
nintedanib,First renewal - idiopathic pulmonary fibrosis (IPF),Primary
nintedanib,Other,
nintedanib,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF),Primary
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through newborn screening,Primary
nitisinone,hereditary tyrosinemia type 1 (HT-1) - for patients identified through prenatal genetic testing,Primary
NSAIDdiflu,Ankylosing Spondylitis,Primary
NSAIDdiflu,Gout,Primary
NSAIDdiflu,Rheumatoid Arthritis,Primary
NSAIDdiflu,Lupus,Primary
NSAIDdiflu,Other,
NSAIDdiflu,Psoriatic Arthritis,Primary
NSAIDflur,Psoriatic Arthritis,Primary
NSAIDflur,Ankylosing Spondylitis,Primary
NSAIDflur,Diagnosis of gout,Primary
NSAIDflur,Other,
NSAIDflur,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
NSAIDflur,Lupus,Primary
NSAIDflur,Rheumatoid Arthritis,Primary
NSAIDindo,Psoriatic Arthritis,Primary
NSAIDindo,Ankylosing Spondylitis,Primary
NSAIDindo,Gout,Primary
NSAIDindo,Lupus,Primary
NSAIDindo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
NSAIDindo,Other,
NSAIDindo,Rheumatoid Arthritis,Primary
NSAIDketo,Other,
NSAIDketo,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
NSAIDketo,Lupus,Primary
NSAIDketo,Gout,Primary
NSAIDketo,Ankylosing Spondylitis,Primary
NSAIDketo,Psoriatic Arthritis,Primary
NSAIDketo,Rheumatoid Arthritis,Primary
NSAIDketoSR,Rheumatoid Arthritis,Primary
NSAIDketoSR,Psoriatic Arthritis,Primary
NSAIDketoSR,Ankylosing Spondylitis,Primary
NSAIDketoSR,Gout,Primary
NSAIDketoSR,Lupus,Primary
NSAIDketoSR,"Treatment failure on optimal dose, or intolerance to, at least one of enteric-coated ASA, ibuprofen, or naproxen",Primary
NSAIDketoSR,Other,
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - liver biopsy results consistent with PBC,Primary
OBE,Obeticholic acid will be used as monotherapy in patient,Primary
OBE,Obeticolic acid will be used in combination with ursodeoxycholic acid (UDCA),Primary
OBE,For treatment of adult patient with confirmed diagnosis of primary billary cholangitis (PBC) - positive antimitochondrial antibodies,Primary
OBE,Other,
ocrelizumab,Other,
ocrelizumab,As treatment for Early Primary Progressive Multiple Sclerosis (PPMS),Primary
ofloxacin,Other,
ofloxacin,Failure or intolerance to first-line agents (e.g. aminoglycosides),Primary
olan,"Diagnosis of Bipolar I disorder AND treatment failure or intolerance to lithium, carbamazepine or divalproex sodium AND treatment failure or intolerance to at least one other specified anti-psychotic agent",Primary
olan,Diagnosis of Schizophrenia AND treatment failure or intolerance to at least one other specified anti-psychotic agent,Primary
olan,Other,
olan,Diagnosis of other psychosis (not dementia related) AND treatment failure or intolerance to at least one other specified anti-psychotic agent,Primary
omnipod,Other form of diabetes (please specify):,Primary
omnipod,Type 1 diabetes,Primary
onabot,"Treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) associated with multiple sclerosis or subcervical spinal cord injury,",Primary
onabot,Treatment of equinus foot deformity due to spasticity in pediatric Cerebral Palsy patients 2 years of age or older.,Primary
onabot,Treatment of strabismus,Primary
onabot,Treatment of overactive bladder (OAB) in adult patients,Primary
onabot,Other,
onabot,Treatment of blepharospasm.,Primary
onabot,Treatment of spasmodic torticollis,Primary
onabot,"Treatment of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults.",Primary
otherInsulinPumpNotApproved,Other form of diabetes (please specify):,Primary
otherInsulinPumpNotApproved,Type 1 diabetes,Primary
Pagetsalen,Diagnosis of Paget's disease,Primary
Pagetsalen,Other,
Pagetsrise,other,
Pagetsrise,diagnosis of Paget's disease,Primary
PAH1,For the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH),Primary
PAH1,Other,
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH)",Primary
PAH2,"As monotherapy, for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH)",Primary
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - inadequate response to the non-prostanoid therapies,Primary
PAH4,For the treatment of functional class IV pulmonary arterial hypertension (PAH) - contraindication to the non-prostanoid therapies,Primary
PAH4,Other,
PAH5,PAH associated with connective tissue disorders,Primary
PAH5,PAH associated with congenital heart disease,Primary
PAH5,Adult patient with World Health Organization / New York Heart Association functional class III PAH whose symptoms are inadequately controlled with a phosphodiesterase-type 5 inhibitor and endothelin receptor antagonist:,Primary
PAH5,Other,
PAH5,Heritable PAH,Primary
PAH5,Idiopathic pulmonary arterial hypertension (PAH),Primary
pamidronate,Diagnosis indicating bone metastases associated with cancer (except breast cancer),Primary
pamidronate,Other,
pentazocine,Patient has experienced treatment failure or intolerance to at least two identified opioids,Primary
pentazocine,Other,
pentazocine,For pain management in a specified pain diagnosis,Primary
pimecro,Diagnosis of eczema - intolerant to topical corticosteroid treatment,Primary
pimecro,Diagnosis of eczema - refractory to three months of potent topical corticosteroid therapy,Primary
pimecro,Other,
pirfenidone,Initial - For the treatment of adult patients who have a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF),Primary
pirfenidone,First renewal - idiopathic pulmonary fibrosis (IPF),Primary
pirfenidone,Second and subsequent renewal - idiopathic pulmonary fibrosis (IPF),Primary
pirfenidone,Other,
piroxicam,Psoriatic Arthritis,Primary
piroxicam,Rheumatoid Arthritis,Primary
piroxicam,Lupus,Primary
piroxicam,Ankylosing Spondylitis,Primary
piroxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
piroxicam,Other,
piroxicam,Gout,Primary
prami,For the treatment of idiopathic Parkinson's disease - other,Primary
prami,Other,
prami,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy,Primary
prami,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa,Primary
propranolol,initial - proliferating infantilei hemangioma requiring systemic therapy,Primary
propranolol,renewal - proliferating infantilei hemangioma requiring systemic therapy,Primary
prostaglandin,Other,
prostaglandin,Erectile dysfunction that occurs as a result of vascular or neurological damage that precludes adequate filling of the sinusoidal spaces,Primary
ralox,Other,
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - unsatisfactory clinical response, defined as a new fragility fracture after 1 year adherence to alendronate or alendronate plus cholecalciferol or risedronate therapy",Primary
ralox,"Clinical or radiographically-documented fracture due to osteoporosis - intolerable side effects to a minimum 1 month trial of oral bisphosphonates, alendronate or risedronate",Primary
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
Rebif,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - unable to achieve adequate control despite taking the maximum tolerated dose of lactulose,Primary
rifaximin,Reducing the risk of overt hepatic encephalopathy (HE) recurrence - hospitalized with HE associated with cirrhosis of the live,Primary
rifaximin,Other,
risan,Other,
risan,Plaque Psoriasis,Primary
ritux,Rheumatoid Arthritis,Primary
ritux,Multiple Sclerosis,Primary
ritux,Other,
ritux,Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA),Primary
ropinirole,For the treatment of idiopathic Parkinson's disease - receiving treatment with levodopa and requires additional adjunctive therapy,Primary
ropinirole,For the treatment of idiopathic Parkinson's disease - cannot tolerate or has contraindications to levodopa,Primary
ropinirole,For the treatment of idiopathic Parkinson's disease - other,Primary
ropinirole,Other,
rotig,"For the treatment of advanced stage Parkinson’s disease, when the patient is receiving treatment with levodopa AND requires additional adjunctive therapy",Primary
rotig,Other,
rufinamide,For the treatment of Lennox-Gastaut syndrome (LGS),Primary
rufinamide,Other,
sarilumab,Rheumatoid Arthritis,Primary
sarilumab,Other,
secukinumab,Plaque Psoriasis,Primary
secukinumab,Other,
secukinumab,Psoriatic Arthritis,Primary
secukinumab,Ankylosing Spondylitis,Primary
semaglutide,Other,
semaglutide,Type 2 diabetes - trial of one agent,Primary
semaglutide,Type 2 diabetes - Dual therapy of metformin and an insulin,Primary
semaglutide,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea,Primary
SGLT2,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea,Primary
SGLT2,Type 2 diabetes - Dual therapy of metformin and an insulin,Primary
SGLT2,Type 2 diabetes - trial of one agent,Primary
SGLT2,Other,
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH),Primary
sildenafil,Other,
sildenafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH),Primary
solifen,Who have developed SEVERE intolerance to immediate-release oxybutynin requiring discontinuation of oxybutynin,Primary
solifen,Overactive Bladder Syndrome,Primary
somatropin,For chronic renal insufficiency,Primary
somatropin,For true growth hormone deficiency ,Primary
somatropin,Other,
sovaldi,genotype 3 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 24 weeks.,Primary
sovaldi,genotype 2 - Treatment-naive or treatment-experienced¹ with no cirrhosis or with compensated cirrhosis²: (with RBV) for 12 weeks.,Primary
statinsfluv,Other,
statinsfluv,Results of trial to rosuvastatin - Other,Primary
statinsfluv,Results of trial to rosuvastatin - Intolerance,Primary
statinsfluv,Results of trial to atorvastatin - Intolerance,Primary
statinsfluv,Results of trial to atorvastatin - Treatment failure,Primary
statinsfluv,Results of trial to atorvastatin - Other,Primary
statinsfluv,Results of trial to rosuvastatin - Treatment failure,Primary
statinslova,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin",Primary
statinslova,Other,
statinsprav,"Treatment failure on optimal doses of, OR specified intolerance to BOTH reference drugs: atorvastatin AND rosuvastatin",Primary
statinsprav,Other,
statinssimv,Results of trial to rosuvastatin - Other,Primary
statinssimv,Other,
statinssimv,Results of trial to rosuvastatin - Treatment failure,Primary
statinssimv,Results of trial to atorvastatin - Other,Primary
statinssimv,Results of trial to atorvastatin - Treatment failure,Primary
statinssimv,Results of trial to rosuvastatin - Intolerance,Primary
statinssimv,Results of trial to atorvastatin - Intolerance,Primary
stiripen,Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome),Primary
stiripen,Other,
sulindac,Rheumatoid Arthritis,Primary
sulindac,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
sulindac,Psoriatic Arthritis,Primary
sulindac,Ankylosing Spondylitis,Primary
sulindac,Other,
sulindac,Lupus,Primary
sulindac,Gout,Primary
sumatrip,Oral absorption is not practical.,Primary
sumatrip,Other,
sumatrip,Nausea and vomiting prevents swallowing oral preparations,Primary
tacrotopical,Diagnosis of eczema - is intolerant to topical corticosteroid treatment,Primary
tacrotopical,Diagnosis of eczema - is refractory to three months of potent topical corticosteroid therapy,Primary
tacrotopical,Other,
tadalafil,Other,
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH),Primary
tadalafil,As monotherapy for the treatment of World Health Organization (WHO) / New York Heart Association (NYHA) functional class III pulmonary arterial hypertension (PAH),Primary
tenofovir,Other - Hepatitis B reactivation prophylaxis while on immunosuppressant(s),Primary
tenofovir,Other,
tenofovir,Viral breakthrough while on treatment (lamivudine resistance),Primary
tenofovir,Viral breakthrough while on treatment (adefovir experienced with persistant viremia and lamivudine resistance),Primary
tenofovir,Chronic Hepatitis B,Primary
tenofovir,Other - patient is pregnant; to reduce vertical transmission of Hepatitis B,Primary
tenoxicam,Rheumatoid Arthritis,Primary
tenoxicam,Psoriatic Arthritis,Primary
tenoxicam,Ankylosing Spondylitis,Primary
tenoxicam,Gout,Primary
tenoxicam,Lupus,Primary
tenoxicam,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
tenoxicam,Other,
terbinafine,Diagnosis of severe onychomycosis,Primary
terbinafine,Other,
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - switch,Primary
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - renewal,Primary
teriflunomide,As monotherapy for the treatment of relapsing-remitting multiple sclerosis - initial,Primary
testosteronecypi,For the treatment of testosterone deficiency in - female-to-male transformation,Primary
testosteronecypi,For the treatment of testosterone deficiency in - pituitary tumour,Primary
testosteronecypi,For the treatment of testosterone deficiency in - removal of pituitary gland,Primary
testosteronecypi,For the indication of documented low testosterone levels due to - surgery of pituitary gland,Primary
testosteronecypi,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome,Primary
testosteronecypi,Other,
testosteronecypi,For the treatment of testosterone deficiency in - undescended testes,Primary
testosteronecypi,For the treatment of testosterone deficiency in - Klinefelter's syndrome,Primary
testosteronecypi,For the treatment of testosterone deficiency in - hypogonadism,Primary
testosteronecypi,For the treatment of testosterone deficiency in - orchiectomy,Primary
testosteroneenan,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome,Primary
testosteroneenan,Other,
testosteroneenan,For the treatment of testosterone deficiency in - orchiectomy,Primary
testosteroneenan,For the indication of documented low testosterone levels due to - surgery of pituitary gland,Primary
testosteroneenan,For the treatment of testosterone deficiency in - hypogonadism,Primary
testosteroneenan,For the treatment of testosterone deficiency in - pituitary tumour,Primary
testosteroneenan,For the treatment of testosterone deficiency in - female-to-male transformation,Primary
testosteroneenan,For the treatment of testosterone deficiency in - Klinefelter's syndrome,Primary
testosteroneenan,For the treatment of testosterone deficiency in - undescended testes,Primary
testosteroneenan,For the treatment of testosterone deficiency in - removal of pituitary gland,Primary
testosteroneprop,For the treatment of testosterone deficiency in - removal of pituitary gland,Primary
testosteroneprop,For the indication of documented low testosterone levels due to - surgery of pituitary gland,Primary
testosteroneprop,For the indication of documented low testosterone levels due to - AIDS-wasting syndrome,Primary
testosteroneprop,For the treatment of testosterone deficiency in - pituitary tumour,Primary
testosteroneprop,For the treatment of testosterone deficiency in - female-to-male transformation,Primary
testosteroneprop,For the treatment of testosterone deficiency in - hypogonadism,Primary
testosteroneprop,For the treatment of testosterone deficiency in - orchiectomy,Primary
testosteroneprop,For the treatment of testosterone deficiency in - undescended testes,Primary
testosteroneprop,For the treatment of testosterone deficiency in - Klinefelter's syndrome,Primary
testosteroneprop,Other,
tiaprofenic,Rheumatoid Arthritis,Primary
tiaprofenic,Diagnosis of gout,Primary
tiaprofenic,Lupus,Primary
tiaprofenic,Ankylosing Spondylitis,Primary
tiaprofenic,Psoriatic Arthritis,Primary
tiaprofenic,Other,
tiaprofenic,"Treatment failure on optimal doses of or intolerance to , ALL of the following: ibuprofen, naproxen (regular release), diclofenac, AND either celecoxib or meloxicam",Primary
ticag,Undergoing revascularization via percutaneous coronary intervention (PCI) secondary to ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) or unstable angina,Primary
ticag,Other,
ticag,Definite stent thrombosis after revascularization with percutaneous coronary intervention (PCI),Primary
ticag,Recurrent ST or non-ST elevation myocardial infarction (STEMI or NSTEMI) after revascularization with percutaneous coronary intervention (PCI),Primary
ticag,Recurrent unstable angina after revascularization with percutaneous coronary intervention (PCI),Primary
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - treatment failure with ASA",Primary
ticlo,"Secondary prevention of coronary, cerebral and peripheral vascular occlusion and embolization - intolerance to ASA",Primary
ticlo,Other,
tinzaparin,Treatment of venous thromboembolism,Primary
tinzaparin,Other,
tinzaparin,Prophylaxis of venous thromboembolism,Primary
tinzaparin,Treatment of venous thromboembolism associated with cancer,Primary
tizan,Diagnosis of spasticity - treatment failure with diazepam,Primary
tizan,Other,
tizan,Diagnosis of spasticity - intolerance to diazepam,Primary
tizan,Diagnosis of spasticity - treatment failure with baclofen,Primary
tizan,Diagnosis of spasticity - intolerance to baclofen,Primary
tobi,Chronic pulmonary Pseudomonas aeruginosa infections,Primary
tobi,Moderate to severe cystic fibrosis,Primary
tobi,Other,
tobi,Does not tolerate injectable forms of tobramycin to manage inhalation issues,Primary
tociliz,Polyarticular Juvenile Idiopathic Arthritis (pJIA),Primary
tociliz,Giant Cell Arteritis (GCA),Primary
tociliz,Rheumatoid Arthritis,Primary
tociliz,Other,
tociliz,Systemic Juvenile Idiopathic Arthritis (sJIA),Primary
tofacitinib,Ulcerative Colitis,Primary
tofacitinib,Rheumatoid Arthritis,Primary
tofacitinib,Other,
tretinoin,Diagnosis of acne,Primary
tretinoin,Diagnosis of skin cancer,Primary
tretinoin,Other,
Twynsta,Patient has experienced intractable cough or angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I) AND is currently taking stable doses of both telmisartan and amlodipine,Primary
Twynsta,Other,
TZDpio,Other,
TZDpio,Type 2 diabetes - trial of one agent,Primary
TZDpio,Type 2 diabetes - Dual therapy of metformin and an insulin,Primary
TZDpio,Type 2 diabetes - Dual therapy of metformin and a sulfonylurea,Primary
uste,Plaque Psoriasis,Primary
uste,Other,
valganciclovir,Other,
valganciclovir,"For the prophylaxis of cytomegalovirus (CMV) infection post stem cell transplant, in patients who test positive for CMV upon polymerase chain reaction (PCR) laboratory testing.",Primary
vancomycin,"Treatment of symptomatic Clostridium Difficile Infection (CDI) - intolerant or cannot take metronidazole (e.g., pregnant women, alcoholism)",Primary
vancomycin,Treatment of symptomatic Clostridium Difficile Infection (CDI) - failed to respond to 4-6 days of oral metronidazole 500mg three times daily,Primary
vancomycin,symptomatic C. Difficile Infection (CDI) - symptoms of moderate to severe disease OR is experiencing a second disease recurrence (within 2-8 weeks of diagnosis of a previous episode),Primary
vancomycin,"symptomatic C. Difficile Infection (CDI) - initiated on vancomycin as an inpatient (e.g. in a hospital setting, nursing home, or long-term care facility) and requires continuation",Primary
vancomycin,Other,
vedoIV,Moderate to Severe Active Crohn's,Primary
vedoIV,Fistulizing Crohn's,Primary
vedoIV,Ulcerative Colitis,Primary
voriconazole,For continuation of hospital-initiated treatment of culture proven invasive candidiasis with documented resistance to fluconazole,Primary
voriconazole,Other,
voriconazole,For continuation of hospital-initiated treatment of invasive aspergillosis,Primary
vosevi,Genotype 2 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 3 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 3 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,"Genotype 3 - Exceptional Request: treatment naïve, F4 cirrhosis",Primary
vosevi,Genotype 4 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 4 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 5 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks,Primary
vosevi,Genotype 6 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks,Primary
vosevi,Unable to verify genotype - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Unable to verify genotype - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 2 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 1 - Previously treated with sofosbuvir containing regimen without an NS5A inhibitor: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
vosevi,Genotype 1 - Previously treated with an NS5A inhibitor-containing regimen: sofosbuvir plus velpatasvir plus voxilaprevir for 12 weeks.,Primary
ypsoPump,Type 1 diabetes,Primary
ypsoPump,Other form of diabetes (please specify):,Primary
zepatier,Genotype 1b - treatment-experienced (prior on-treatment virologic failures): 12 weeks,Primary
zepatier,Genotype 1a or 1b - treatment-experienced (prior relapsers): 12 weeks,Primary
zepatier,Genotype 4 - treatment-naïve: 12 weeks,Primary
zepatier,Genotype 4 - treatment-experienced (prior relapsers): 12 weeks,Primary
zepatier,Genotype 4 - treatment-experienced (prior on-treatment virologic failures) with RBV: 16 weeks,Primary
zepatier,Genotype 1a - treatment-experienced (prior on-treatment virologic failures): 16 weeks,Primary
zepatier,Genotype 1b - treatment-naïve: 12 weeks,Primary
zepatier,Genotype 1a - treatment-naïve: 12 weeks,Primary
zip,Other,
zip,Other psychosis (not dementia related),Primary
zip,Diagnosis of schizophrenia,Primary
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least two specified benzodiazepines and one other specified hypnotic agent",Primary
zopiclone,For the treatment of insomnia - history of drug or alcohol addiction,Primary
zopiclone,Other,
zopiclone,"For the treatment of insomnia - intolerant to, or failed on, at least three specified benzodiazepines",Primary
zopiclone,For the treatment of insomnia - identified psychiatric diagnosis,Primary
zopiclone,For the treatment of insomnia - HIV/AIDS,Primary
zopiclone,"For the treatment of insomnia - fragile, elderly patient",Primary
